{"schema_version":"secwatch.filing_event.v1","accession":"0001000694-25-000024","form_type":"8-K","ticker":"NVAX","cik":"0001000694","company_name":"NOVAVAX INC","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.116135+00:00","generated_at":"2026-05-22T02:51:19.231999+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Novavax Q1 revenue $667M, net income $519M; raises FY guidance to $975M-$1.025B","bullets":["Total revenue $667M vs $94M YoY; net income $519M vs net loss $148M.","Raises full-year adjusted total revenue framework to $975M-$1,025M (from $300-$350M).","FDA BLA review on track; approval triggers $175M milestone from Sanofi; MAs to Sanofi by Q4 2025.","Strengthened Takeda partnership: $20M upfront, annual milestones plus royalties on Japan sales.","SHIELD-Utah: Nuvaxovid recipients had ~39% fewer reactogenicity symptoms vs mRNA vaccine."],"urls":{"canonical":"https://secwatch.observer/filing/0001000694-25-000024","json":"https://secwatch.observer/filing/0001000694-25-000024.json","markdown":"https://secwatch.observer/filing/0001000694-25-000024.md","text":"https://secwatch.observer/filing/0001000694-25-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000694/000100069425000024/0001000694-25-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000694/000100069425000024/nvax-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T02:51:19.231999+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}